Anti-Müllerian hormone: Correlation with testosterone and oligo- Or amenorrhoea in female adolescence in a population-based cohort study

Human Reproduction (Impact Factor: 4.57). 07/2014; 29(10). DOI: 10.1093/humrep/deu182
Source: PubMed


STUDY QUESTIONS Can serum anti-Müllerian hormone (AMH) levels measured in female adolescents predict polycystic ovary syndrome (PCOS)-associated
features in adolescence and early adulthood?

Download full-text


Available from: Hany Lashen, Jul 30, 2014
  • Source
    • "It can also be difficult to estimate the share of the physiological and pathological, concerning acne and cycle disorders. Serum AMH assay is therefore a true alternative , as it is recommended by the American association of clinical endocrinologists[83]. Adolescents with PCOS have higher serum AMH levels, with a thresholds set at 30 pmol/L[84], which is in the range of values found in the literature for older PCOS women[85,86]. However, it must be noticed that the thresholds for excessive AFC or high serum AMH level have to be reviewed and validated worldwide, since recent technical developments in ultrasound and assays could lead to their modification. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Polycystic ovary syndrome (PCOS) is the most common cause of chronic anovulation and hyperandrogenism in young women. Excessive ovarian production of Anti-Müllerian Hormone, secreted by growing follicles in excess, is now considered as an important feature of PCOS. The aim of this review is first to update the current knowledge about the role of AMH in the pathophysiology of PCOS. Then, this review will discuss the improvement that serum AMH assay brings in the diagnosis of PCOS. Last, this review will explain the utility of serum AMH assay in the management of infertility in women with PCOS and its utility as a marker of treatment efficiency on PCOS symptoms. It must be emphasized however that the lack of an international standard for the serum AMH assay, mainly because of technical issues, makes it difficult to define consensual thresholds, and thus impairs the widespread use of this new ovarian marker. Hopefully, this should soon improve.
    Full-text · Article · Dec 2015 · Reproductive Biology and Endocrinology
  • Source
    • "pooled the results of all study subjects for the correlation of AMH with metabolic indices, which may have diluted any observed effect inherently related to the pathophysiology of PCOS. In all mentioned studies, AMH was shown to be elevated in women with PCOS compared to healthy controls [31] [32] [37] [38], in correspondence with other literature [21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The final hallmark of diminishing ovarian reserve is menopause, a state known to be inextricably linked to the deterioration of female cardiovascular health. The menopausal transition is associated with an increased risk of future cardiovascular morbidity and mortality, irrespective of chronological age. The aim of this narrative review is to identify studies investigating the association between Anti-Müllerian Hormone (AMH), a marker of ovarian reserve status, and factors of cardio-metabolic risk. Both for regularly cycling women and women with polycystic ovary syndrome (PCOS), current reports are conflicting and heterogeneous, with some indicating presence and others absence of a correlation between AMH and cardio-metabolic risk factors. The occurrence of hypertensive complications in pregnancy, known to increase the risk of later cardiovascular sequelae, is associated with reduced AMH levels in various study populations. Further research remains a prerequisite in order to further elucidate a possible common mechanism for ovarian and cardiovascular decline. More knowledge of the temporal or causal association between ovarian and cardiovascular decline may enable timely identification of women with increased risk of cardiovascular disease or early onset ovarian aging. Following this, AMH may in the future play a role beyond the scope of female reproduction. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
    Full-text · Article · Jan 2015 · Maturitas
  • [Show abstract] [Hide abstract]
    ABSTRACT: Laboratory models support an inverse association between anti-Müllerian hormone (AMH) and breast tumor development. Human studies are lacking; one study (N=105 cases, 204 controls) with prospectively-collected serum reported the opposite-an approximate 10-fold increase in breast cancer risk comparing 4th to 1st quartile AMH levels. We investigated the relation between serum AMH levels and breast cancer risk in a case-control (N=452 cases, 902 controls) study nested within the prospective Sister Study cohort of 50,884 women. At enrollment, participants were ages 35-54, premenopausal, and completed questionnaires on medical and family history, lifestyle factors, and demographics. AMH (ng/ml) was measured by ultrasensitive ELISA in serum collected at enrollment and log-transformed for analysis. Multivariate conditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI) to account for matching on age and enrollment year. Mean age at enrollment was 46.8 years with an average 2.9 years from blood draw to breast cancer diagnosis (SD=1.9). AMH concentrations were below the limit of detection (0.003 ng/ml) for ~25% of samples. Compared with samples below the LOD, women with AMH >2.84 ng/ml (90th percentile among controls) had a two-fold increase in breast cancer odds (OR=2.25; 95% CI: 1.26-4.02). For each 1-unit increase in lnAMH, overall breast cancer odds increased by 8% (OR=1.08; 95% CI: 1.02-1.15) and odds of ER-positive, invasive disease increased by 15% (OR=1.15; 95% CI: 1.05-1.25). Our findings demonstrate an overall positive relation between AMH and breast cancer. Copyright © 2015, American Association for Cancer Research.
    No preview · Article · Apr 2015 · Cancer Prevention Research
Show more